What is the appropriate treatment regimen for sigmoid sinus thrombosis using enoxaparin (Clexane) and rivaroxaban?

Treatment of Sigmoid Sinus Thrombosis

For sigmoid sinus thrombosis, initiate anticoagulation with enoxaparin 1 mg/kg subcutaneously every 12 hours (or 1.5 mg/kg once daily) followed by transition to rivaroxaban 15 mg orally twice daily with food for 21 days, then 20 mg once daily with food for at least 3-6 months.

Initial Treatment Phase

Sigmoid sinus thrombosis is a form of cerebral venous sinus thrombosis (CVST) and should be treated as venous thromboembolism (VTE). The treatment approach follows established VTE protocols with specific considerations for intracranial location.

Enoxaparin (Clexane) Dosing

Start immediately with enoxaparin 1:

• 1 mg/kg subcutaneously every 12 hours, OR
• 1.5 mg/kg subcutaneously once daily

This initial parenteral anticoagulation phase typically lasts 5-10 days and provides rapid, predictable anticoagulation while diagnostic workup continues and oral therapy is initiated 2, 3.

Transition to Rivaroxaban

Rivaroxaban dosing for VTE treatment 1, 4:

• Days 1-21: 15 mg orally twice daily WITH FOOD
• Day 22 onward: 20 mg once daily WITH FOOD

The twice-daily dosing for the first 21 days provides higher initial drug exposure for acute thrombus treatment, then transitions to once-daily maintenance dosing 1, 4.

Duration of Anticoagulation

Minimum 3-6 months of anticoagulation is recommended 3. For sigmoid sinus thrombosis specifically:

• If provoked by a clear transient risk factor (e.g., acute otitis media, mastoiditis): 3 months minimum
• If unprovoked or with persistent risk factors: Consider extended anticoagulation beyond 6 months 3
• Reassess at 3-6 months with repeat imaging to evaluate recanalization 5

Important Clinical Considerations

Renal Function

• CrCl ≥30 mL/min: Use standard rivaroxaban dosing as above
• CrCl 15-30 mL/min: Consider rivaroxaban 15 mg once daily (not twice daily) or continue enoxaparin with dose adjustment
• CrCl <15 mL/min: Avoid rivaroxaban; continue enoxaparin with careful monitoring 4

When to Avoid Rivaroxaban

• Severe hepatic impairment (Child-Pugh B or C)
• Severe renal impairment (CrCl <15 mL/min)
• Active pathological bleeding
• Malabsorption syndromes affecting oral medication 4

Monitoring

For enoxaparin:

• No routine monitoring needed in most patients
• Consider anti-Xa levels in patients with renal impairment (CrCl <30 mL/min), obesity (BMI >40), or extremes of weight 6

For rivaroxaban:

• No routine coagulation monitoring required
• Assess renal function before starting and periodically during treatment
• Monitor for signs of bleeding 4

Evidence Supporting This Approach

The recommendation prioritizes rivaroxaban over warfarin based on moderate-certainty evidence showing DOACs are as effective as warfarin with lower bleeding risk 3. While specific large trials for CVST are limited, recent prospective data demonstrates rivaroxaban achieves 87.9% recanalization rates in CVST with no major bleeding events 5.

Enoxaparin bridging is recommended because rivaroxaban requires the initial twice-daily loading phase, and immediate therapeutic anticoagulation is critical in acute thrombosis 1. The 5-10 day overlap ensures therapeutic anticoagulation throughout the transition period.

Alternative: Direct Rivaroxaban Start

If enoxaparin is unavailable or contraindicated, rivaroxaban can be started directly at 15 mg twice daily with food for 21 days, then 20 mg once daily 1, 4. However, the initial bridging with enoxaparin provides more predictable anticoagulation in the acute phase.

Special Populations

Cancer-associated thrombosis: If sigmoid sinus thrombosis occurs in a patient with active cancer, enoxaparin 1 mg/kg twice daily or 1.5 mg/kg once daily may be continued long-term as monotherapy, as it has superior efficacy to warfarin in this population 2, 6. However, rivaroxaban and apixaban are now preferred over LMWH in cancer-associated VTE based on recent evidence 3.

Pediatric patients: Limited data exists for rivaroxaban in children. Case reports demonstrate successful treatment with enoxaparin bridging to rivaroxaban in pediatric CVST 7, 8, but this remains off-label use requiring careful risk-benefit assessment.

Common Pitfalls

1. Underdosing rivaroxaban: The VTE treatment dose is 15 mg twice daily initially, NOT the 10 mg once daily used for prophylaxis 1
2. Missing the food requirement: Rivaroxaban 15 mg and 20 mg tablets MUST be taken with food to ensure adequate absorption 4
3. Premature discontinuation: Ensure minimum 3-month treatment course even if symptoms resolve earlier 3
4. Failure to assess recanalization: Repeat imaging at 3-6 months guides duration decisions 5